Tony is a senior partner with Gowling WLG and past Head of its IP Litigation & Strategy Group. His primary focus has been on chemical, biotech, and pharmaceutical patent litigation. His practice also includes trademark litigation, regulatory issues, and advising on IP life-cycle matters. He regularly appears in the Federal Court (both trial and appeal), as well as the SCC on patent matters, including questions of patentability of life forms, patent licensing, and the infringement of biotech patents. Important cases he has appeared in include the SCC decisions in Monsanto v. Schmeiser and Apotex v. Sanofi-Synthelabo (a case for which Tony, as lead partner, won the Milestone Case of the Year 2014 and Patent Case of the Year 2009 awards given by Managing Intellectual Property (MIP). Recently, he represented Novartis in protecting its patent on Gleevec and Biotech Canada in an access-to-information case before the SCC. He has been recognized in Chambers Global, Chambers Canada, The Best Lawyers in Canada, and The Canadian Legal Lexpert® Directory, among other directories. He received MIP’s IP Practitioner of the Year 2014 award. In 2019 and 2020, MIP ranked Tony both as a patent and a trademark “star” and he maintained his gold tier standing for patent litigation in IAM Patent 1000.